BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/14/2018 11:38:00 AM | Browse: 938 | Download: 1240
 |
Received |
|
2018-03-30 09:07 |
|
Peer-Review Started |
|
2018-03-30 09:21 |
|
To Make the First Decision |
|
2018-05-02 03:41 |
|
Return for Revision |
|
2018-05-03 06:36 |
|
Revised |
|
2018-06-11 09:08 |
|
Second Decision |
|
2018-06-27 08:10 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2018-06-28 15:29 |
|
Articles in Press |
|
2018-06-28 15:29 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2018-09-11 07:21 |
|
Publish the Manuscript Online |
|
2018-09-14 11:38 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Retrospective Study |
| Article Title |
FOLFIRI3-aflibercept in previously treated patients with metastatic colorectal cancer
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Candice Carola, Francois Ghiringhelli, Stefano Kim, Thierry Andre, Juliette Barlet, Leila Bengrine-Lefevre, Helene Marijon, Marie-Line Garcia-Larnicol, Christophe Borg, Linda Dainese, Nils Steuer, Hubert Richa, Magdalena Benetkiewicz, Annette K Larsen, Aimery de Gramont and Benoist Chibaudel |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Benoist Chibaudel, MD, Department of Medical Oncology, Franco-British Institute, 4 rue Kléber, Levallois-Perret 92300, France. benoist.chibaudel@ihfb.org |
| Key Words |
Chemotherapy; Irinotecan; Aflibercept; Second-line; Colorectal cancer |
| Core Tip |
Results obtained in this retrospective study show that minimally modified FOLFIRI has improvement dramatically the efficacy of the FOLFIRI3-aflibercept combination with high response rates and survivals in patients with previously treated metastatic colorectal cancer, whatever prior use of irinotecan. A prospective randomized trial is planned to compare FOLFIRI-aflibercept to FOLFIRI3-aflibercept. |
| Publish Date |
2018-09-14 11:38 |
| Citation |
Carola C, Ghiringhelli F, Kim S, André T, Barlet J, Bengrine-Lefevre L, Marijon H, Garcia-Larnicol ML, Borg C, Dainese L, Steuer N, Richa H, Benetkiewicz M, Larsen AK, de Gramont A, Chibaudel B. FOLFIRI3-aflibercept in previously treated patients with metastatic colorectal cancer. World J Clin Oncol 2018; 9(5): 110-118 |
| URL |
http://www.wjgnet.com/2218-4333/full/v9/i5/110.htm |
| DOI |
http://dx.doi.org/10.5306/wjco.v9.i5.110 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
